Sign In
Buy VYGR
$3.60
+0.0100 (+0.279%)
At Close: Jun 03, 2026
Voyager Therapeutics Stock Soars On License Option Pact With Pfizer
08:25am, Wednesday, 06'th Oct 2021
Voyager Therapeutics Inc (NASDAQ: VYGR) has announced licensing option agreement with Pfizer Inc (NYSE: PFE) for capsids generated from Voyager's RNA-driven TRACER screening technology. Related:
Voyager Therapeutics stock rockets after license option deal with Pfizer that could be valued at $630 million
07:32am, Wednesday, 06'th Oct 2021
Shares of Voyager Therapeutics Inc. VYGR, -3.52% rocketed 38.9% in premarket trading Wednesday, after closing at a record low in the previous session, after the gene therapy company announced a licens
Voyager receives $30 million up front with potential option exercise fees and milestone payments of up to $600 million plus product sales-based royalties
Voyager Therapeutics to Participate in Upcoming Investor Conferences
05:08pm, Thursday, 02'nd Sep 2021
CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation platform technologies, to
Voyager Therapeutics to Participate in Upcoming Investor Conferences
04:20pm, Tuesday, 10'th Aug 2021
CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation platform technologies, tod
Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates
10:04am, Monday, 09'th Aug 2021
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -6.67% and -66.41%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Proprietary AAV capsids to power second-generation efforts in Huntington's disease and ALS, pre-clinical programs in spinal muscular atrophy and diseases linked to GBA1 mutations
Voyager CEO Resigns After Company Turns Back To Discovery-Stage
09:30am, Thursday, 20'th May 2021
Voyager Therapeutics, Inc (NASDAQ: VYGR) CEO and President Andre Turenne will step down as the beleaguered company announced it would move focus to early, discovery-stage efforts. The company's CMO
Voyager Therapeutics Announces Strategic Shift and Leadership Transitions
04:01pm, Wednesday, 19'th May 2021
Company focusing on rapidly moving VY-HTT01 into clinical development for Huntington's disease and maximizing opportunities created by TRACER TM gene therapy technology platform and next-generation ta
Voyager Therapeutics' Vectorized Anti-Tau Antibody Shows Encouraging Preclinical Data In CNS Disorders
10:20am, Wednesday, 12'th May 2021
Voyager Therapeutics Inc (NASDAQ: VYGR) has announced new preclinical data characterizing the durable expression and activity of a vectorized anti-tau antibody. The results will be presented at th
Voyager Therapeutics Presents New Preclinical Data Showing Reduction of Pathological Tau with Vectorized Anti-Tau Antibody
07:30am, Wednesday, 12'th May 2021
Findings to be presented at the 24 th Annual Meeting of the American Society of Gene and Cell Therapy
CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for serious neurolog
Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates
09:46am, Monday, 10'th May 2021
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 18.31% and 35.72%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Voyager Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates
07:30am, Monday, 10'th May 2021
- On track to initiate Phase 1/2 trial of VY-HTT01 for Huntington's disease in the fourth quarter of 2021
Strength Seen in Voyager Therapeutics (VYGR): Can Its 16.5% Jump Turn into More Strength?
09:01am, Tuesday, 27'th Apr 2021
Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be mor
